BioMarin Pharmaceutical Inc
BMRN
查看详细走势图
61.150USD
+9.200+17.71%
收盘 12/19, 16:00（美东）报价延迟15分钟
11.75B总市值
22.49市盈率 TTM
盘中分时
1分
30分
1小时
日k
周k
月k
日k
今天
+17.71%
5天
+14.71%
1月
+16.52%
6月
+11.18%
今年开始到现在
-6.97%
1年
-6.87%
查看详细走势图
TradingKey BioMarin Pharmaceutical Inc股票评分
单位: USD 更新时间: 2025-12-19操作建议
BioMarin Pharmaceutical Inc当前公司基本面数据相对非常健康，增长潜力很大。当前估值合理，在药品行业排名22/158位。机构持股占比非常高，近一月多位分析师给出公司评级为买入。最高目标价91.15。中期看，股价处于上升通道。近一个月，市场表现较强，技术面和基本面综合得分较高，较强的走势得到基本面和技术面的印证。目前股价在压力位和支撑位之间，可以做区间波段操作。
BioMarin Pharmaceutical Inc评分
压力支撑
由于公司未披露，未能获取相关数据
多维评测
本期评分
上期评分
分析师目标
根据
28
位分析师
买入
评级
91.147
目标均价
+71.01%
涨幅空间
数据免责声明：分析师评级与目标价由LSEG提供，仅供参考，不应当作投资建议
BioMarin Pharmaceutical Inc亮点
亮点风险
BioMarin Pharmaceutical Inc. is a global biotechnology company engaged in the development of genetic discovery into medicines that make an impact on the life of each patient. The Company has eight commercial therapies and a clinical and preclinical pipeline. Its commercial products include Vimizim (elosulfase alpha), Naglazyme (galsulfase), Palynziq (pegvaliase-pqpz), Brineura (cerliponase alfa), Aldurazyme (laronidase), Roctavian (valoctocogene roxaparvovec), Kuvan (sapropterin dihydrochloride), and Voxzogo (vosoritide). Vimizim is an enzyme replacement therapy for the treatment of MPS IVA, a lysosomal storage disorder. The Roctavian is an adeno-associated virus (AAV5) vector gene therapy designed to restore factor VIII plasma concentrations in patients with severe hemophilia A. Its key clinical programs include Vosoritide, BMN 333, BMN 390, BMN 351, BMN 349, and INZ-701. Its late-stage enzyme replacement therapy, INZ-701, is being developed for the treatment of ENPP1 deficiency.
业绩高增长
公司营业收入稳步增长，连续3年增长36.16%
利润高增长
公司净利润处于行业前列，最新年度总收入2.85B美元
估值低估
公司最新PE估值22.49，处于3年历史低位
机构加仓
最新机构持股187.90M股，环比增加0.04%
ETHSX持仓
明星投资者ETHSX持仓，最新持仓市值17.35K
BioMarin Pharmaceutical Inc新闻
即将为您带来更多新闻，敬请期待。。。
财务指标
每股收益
由于公司未披露，未能获取相关数据
营业总收入
由于公司未披露，未能获取相关数据
BioMarin Pharmaceutical Inc简介
BioMarin Pharmaceutical Inc. is a global biotechnology company engaged in the development of genetic discovery into medicines that make an impact on the life of each patient. The Company has eight commercial therapies and a clinical and preclinical pipeline. Its commercial products include Vimizim (elosulfase alpha), Naglazyme (galsulfase), Palynziq (pegvaliase-pqpz), Brineura (cerliponase alfa), Aldurazyme (laronidase), Roctavian (valoctocogene roxaparvovec), Kuvan (sapropterin dihydrochloride), and Voxzogo (vosoritide). Vimizim is an enzyme replacement therapy for the treatment of MPS IVA, a lysosomal storage disorder. The Roctavian is an adeno-associated virus (AAV5) vector gene therapy designed to restore factor VIII plasma concentrations in patients with severe hemophilia A. Its key clinical programs include Vosoritide, BMN 333, BMN 390, BMN 351, BMN 349, and INZ-701. Its late-stage enzyme replacement therapy, INZ-701, is being developed for the treatment of ENPP1 deficiency.
公司代码BMRN
公司BioMarin Pharmaceutical Inc
CEOHardy (Alexander)
网址https://www.biomarin.com/
常见问题
BioMarin Pharmaceutical Inc(BMRN)的当前股价是多少？
BioMarin Pharmaceutical Inc(BMRN)的当前股价是 61.150。
BioMarin Pharmaceutical Inc的股票代码是什么？
BioMarin Pharmaceutical Inc的股票代码是BMRN。
BioMarin Pharmaceutical Inc股票的52周最高点是多少？
BioMarin Pharmaceutical Inc股票的52周最高点是73.510。
BioMarin Pharmaceutical Inc股票的52周最低点是多少？
BioMarin Pharmaceutical Inc股票的52周最低点是50.760。
BioMarin Pharmaceutical Inc的市值是多少？
BioMarin Pharmaceutical Inc的市值是11.75B。
BioMarin Pharmaceutical Inc的净利润是多少？
BioMarin Pharmaceutical Inc的净利润为426.86M。
现在BioMarin Pharmaceutical Inc(BMRN)的股票是买入、持有还是卖出？
根据分析师评级，BioMarin Pharmaceutical Inc(BMRN)的总体评级为买入，目标价格为91.147。
BioMarin Pharmaceutical Inc(BMRN)股票的每股收益（EPS TTM）是多少
BioMarin Pharmaceutical Inc(BMRN)股票的每股收益（EPS TTM）是2.719。
相关品种
